Navigation Links
Studies Suggest SoundBite Hearing System Offers Advantages Over Bone-Anchored Hearing Implants for Single-Sided Deafness Patients
Date:8/12/2014

SAN MATEO, Calif., Aug. 12, 2014 /PRNewswire/ -- Two recently published peer-reviewed studies suggest that the non-surgical SoundBite™ Hearing System can offer benefits over surgical, osseointegrated Bone-Anchored Hearing Implants (BAHI) for single-sided deafness patients.

Published in the International Journal of Audiology, the first study by Moore et al., "Preliminary Comparison of Bone-Anchored Hearing Instruments and a Dental Device as Treatments for Unilateral Hearing Loss" reports on 9 single-sided deaf patients.  Each study participant wore SoundBite and BAHI for 30 days in randomized order and their experience was compared via the clinically validated APHAB questionnaire and sound field testing. 

The study concludes that SoundBite delivered "consistently greater benefit" for patients compared to BAHI, as assessed by APHAB scores.  Sound field scores aided by each device also were on average 10 decibels better for SoundBite.   After the study, 44% of subjects elected to take an additional step to undergo a procedure to remove their BAHI abutment.

A second recently published study that compared device capabilities may shed light on the reasons for these clinical results.  This study by Syms et al.—entitled "Bone Conduction Hearing: Device Auditory Capability to Aid in Device Selection", published in Otolaryngology – Head & Neck Surgery—evaluated the output of 8 BAHI devices and SoundBite across a full range of audible frequencies. 

The study established that all devices had adequate output across most frequencies, but that SoundBite has advantages in output and gain at high frequencies.  High-frequency device performance is particularly important for hearing in noisy environments and understanding speech. 

"The differences in device performance reported in this study help physicians select the right device for each patient.  We know that high frequency performance is critical to speech understanding and hearing in noise.  SoundBite is a better solution in this range, precisely where single-sided deaf patients need support the most," said Mark J. Syms, M.D. of The Arizona Ear Center, and lead author of the study.

About the patients affected: Single-sided deafness is caused by tumors, trauma, infections, or other illnesses, and is characterized by a significant or permanent hearing loss in one ear and relatively normal hearing in the other ear.  Patients suffer from reduced quality of life among other consequences.

About SoundBite: An innovation in hearing-prosthetic technology, SoundBite transmits sound using the well-established principle of bone conduction to restore the perception of hearing in both ears. Unlike other devices that route sound through skull bones, SoundBite uses the patient's teeth to transfer sound from the impaired ear to the working ear.  This system removes the need for a surgical implant in the skull which eliminates the costs and complications of surgery.  SoundBite is FDA cleared for Single-Sided Deafness and Conductive Hearing Loss in patients age 18 and older.

Sources:

Syms MJ, Hernandez KE, "Bone conduction hearing: device auditory capability to aid in device selection," Otolaryngology-Head & Neck Surgery." 2014, 150: 866-871.

Moore B, Popelka, GR, "Preliminary comparison of bone-anchored hearing instruments and a dental device as treatments for unilateral hearing loss," International Journal of Audiology. 2013, 10: 678-86.

Logo - http://photos.prnewswire.com/prnh/20140812/135522


'/>"/>
SOURCE Sonitus Medical, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
2. First assessment of individual RLS domains in new post-hoc analyses of Neupro® studies
3. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
4. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
5. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
8. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
9. Pulse Oximetry Screening Hailed as the New Milestone to Combat Critical Congenital Heart Disease - Signal Extraction Technology Leading the Way in Large, Independent Clinical Studies
10. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Research and Markets has announced the addition of ... offering. ... report forecasts the global optical transceiver market to grow at a ... report covers the present scenario and the growth prospects of the ... the report considers the revenue generated from the shipment of optical ...
(Date:12/9/2016)...  Harmar Mobility, LLC announced today that Steven E. Dawson has been ... of Directors. Photo - http://photos.prnewswire.com/prnh/20161209/447552 ... Harmar ... Mr. Dawson,s executive career includes leadership roles managing ... of industries. He brings to the company deep operational and leadership expertise, ...
(Date:12/9/2016)... aTyr Pharma, Inc. (Nasdaq: LIFE ), a ... to address severe, rare diseases, today announced that senior management will ... Success Healthcare Conference at the InterContinental Barclay Hotel in ... 4:20 p.m. ET. About aTyr Pharma ... aTyr Pharma is engaged ...
Breaking Medicine Technology:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... The ... Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits and ... the District of Columbia as an education tool in the war against teen drug ...
(Date:12/9/2016)... ... December 09, 2016 , ... Mediaplanet today announces distribution of the latest ... readers to sign up as an organ donor for the 123,000 people in the ... organ donor can save up to 8 saves through organ donation and enhance many ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... "I had ... an inventor from Winchester, Va. "I thought that if the nebulizer had a more ... rather than fearing them." , He developed the patent-pending NEBY to avoid the need ...
(Date:12/8/2016)... ... 08, 2016 , ... The Florida Hospital Tampa Wound Healing ... Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the Institute ... and facilities have earned this distinction. This is the second time the Florida ...
(Date:12/8/2016)... ... 2016 , ... ZyDoc , a New York-based medical ... Capture Methods for Input to Electronic Health Records: A Comparative Usability Study” has ... usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s MediSapien™ natural ...
Breaking Medicine News(10 mins):